Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$29.22 USD

29.22
24,234,574

-0.05 (-0.17%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $29.21 -0.01 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 14% (34 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Is a Beat in Store for Keryx (KERX) This Earnings Season?

Keryx (KERX) is likely to provide updates on the merger with Akebia along with the updates on Auryxia at the second quarter call.

    What's in the Cards for Glaxo (GSK) This Earnings Season?

    Glaxo's (GSK) Pharmaceuticals and Vaccines segments are likely to boost sales in Q2 earnings.

      Is a Beat in Store for Alexion (ALXN) This Earnings Season?

      Alexion is likely to provide details about the pipeline portfolio when it reports its second-quarter 2018 results on Jul 26.

        Sweta Killa headshot

        Healthcare ETFs to Buy on Solid Q2 Earnings Expectations

        With earnings surprises well in the cards, the healthcare sector is expected to witness earnings growth of 9.1% in the second quarter, suggesting continued outperformance for healthcare ETFs.

          Allergan (AGN) to Report Q2 Earnings: What's in the Cards?

          While Allergan's (AGN) Q2 sales are likely to be driven by new as well as established products like Botox and international growth, generic competition for some key products is expected to hurt sales.

            Is a Beat in Store for Bristol-Myers (BMY) in Q2 Earnings?

            Bristol-Myers (BMY) is scheduled to report second-quarter earnings on Jul 26.

              Merck to Cut Price of Few Drugs Amid Drug Pricing Controversy

              Merck (MRK) announces a 60% cut in U.S. list prices for its hepatitis C drug, Zepatier. It will also lower the list price of some other drugs by 10%.

                Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, FDA Approvals

                J&J (JNJ) and Novartis (NVS) kick off earnings for pharma sector on a strong note. FDA approves J&J's latest HIV medicine and line extension of Pfizer's prostate cancer drug.

                  Pfizer & Lilly's Pain Candidate Succeeds in Phase III Study

                  Pfizer (PFE) and Eli Lilly (LLY) announce that their investigational pain candidate, tanezumab, significantly reduces pain in osteoarthritis patients.

                    IBM Beats on Q2 Earnings, z14 Mainframe Aids Top-Line Growth

                    IBM's second-quarter 2018 earnings benefit from higher systems revenues, pre-tax margin expansion and a lower share count.

                      Pfizer's Hemophilia B Gene Therapy Candidate Enters Phase III

                      Pfizer (PFE) initiates phase III program on a gene therapy treatment, fidanacogene elaparvovec, for patients with hemophilia B.

                        Pfizer's Xtandi Gets FDA Nod for Expanded Patient Population

                        FDA approves Pfizer's (PFE) sNDA to expand the label of Xtandi to include the non-metastatic prostate cancer patient population.

                          Novartis Looks to Exit Antibacterial, Antiviral Program

                          Per media sources, Novartis is looking to exit its antibacterial and antiviral research program, and cut its headcount.

                            Pharma Stock Roundup: PFE to Split Into 3 Units, J&J to Pay $4.7B in Talc Lawsuit

                            Pfizer (PFE) is re-organizing its business into three new units, effective 2019. A St Louis jury orders J&J (JNJ) to pay $4.69 billion in a lawsuit related to its talc-based products.

                              Swarup Gupta headshot

                              Dow 30 Stock Roundup: Boeing Q2 Commercial Deliveries Up Y/Y, Pfizer to Reorganize

                              The index enjoyed a strong week of gains, boosted by expectations of a strong second quarter earnings season.

                                Pfizer (PFE) to Reorganize Business Into Three New Units

                                Pfizer (PFE) is re-organizing its business into three business segments, effective 2019. It is separating its consumer healthcare business into a standalone unit.

                                  Is Pfizer (PFE) Outperforming Other Medical Stocks This Year?

                                  Is (PFE) Outperforming Other Medical Stocks This Year?

                                    Merck's Keytruda Gets FDA's Priority Review for Liver Cancer

                                    The FDA grants a priority review to Merck's (MRK) label expansion filing for its key cancer drug Keytruda regarding the first-line treatment of advanced HCC.

                                      Ekta Bagri headshot

                                      3 Gene Therapy Stocks Investors Can Bet on in Rest of 2018

                                      Gene therapy continues to be in focus with the recent spate of deals and acquisitions. We highlight three stocks, which have promising candidates in their pipeline.

                                        Pfizer to Defer Price Increases After Discussion With Trump

                                        Pfizer, Inc. (PFE) to defer its recent price increases of several prescription drugs after discussion with Trump.

                                          Kinjel Shah headshot

                                          Drug Pricing in Focus Again as Trump Tweet Slams Pfizer

                                          In a tweet, Trump says Pfizer and other U.S. drugmakers should be "ashamed" that they have raised drug prices for "no reason".

                                            Clovis Gets EU Acceptance for Rubraca Label Expansion Filing

                                            Clovis Oncology's (CLVS) regulatory application seeking label expansion of Rubraca as maintenance treatment was accepted for review in Europe.

                                              Madhu Goel headshot

                                              3 Buy-Rated Large Cap Pharma Stocks to Boost Health in July

                                              We take a look at the three large cap pharma stocks that might be best bargains for the month of July.

                                                The Zacks Analyst Blog Highlights: Pfizer, BHP, Facebook, Tesla and Humana

                                                The Zacks Analyst Blog Highlights: Pfizer, BHP, Facebook, Tesla and Humana

                                                  Nabaparna Bhattacharya headshot

                                                  Is Pfizer (PFE) a Great Stock for Value Investors?

                                                  Let's see if Pfizer Inc. (PFE) stock is a good choice for value-oriented investors right now from multiple angles.